Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$700.33 +4.31 (+0.62%)

Closing price 02/21/2025 04:00 PM Eastern

Extended Trading

$703.93 +3.60 (+0.51%)

As of 02/21/2025 07:50 PM Eastern

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 25 Analyst Ratings

Sell
1

Hold
6

Buy
18

Based on 25 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 1 has given a sell rating, 6 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for REGN.

Consensus Price Target

$973.13
38.95% Upside

According to the 25 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $973.13. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $165.00. The average price target represents a forecasted upside of 38.95% from the current price of $700.33.

Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

REGN Analyst Ratings Over Time

Type	Current Forecast 2/24/24 to 2/23/25	1 Month Ago 1/25/24 to 1/24/25	3 Months Ago 11/26/23 to 11/25/24	1 Year Ago 2/24/23 to 2/24/24
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	14 Buy rating(s)	17 Buy rating(s)	18 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$973.13	$1,015.38	$1,099.55	$939.05
Forecasted Upside	38.95% Upside	50.25% Upside	46.70% Upside	-4.30% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.76	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	38.95% Upside	29,286.41% Upside	14.35% Upside
News Sentiment Rating	Neutral News See Recent REGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/5/2025	Leerink Partnrs 5 of 5 stars	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/5/2025	Robert W. Baird 2 of 5 stars	Brian Skorney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$940.00 ➝ $759.00	+5.08%
2/5/2025	Leerink Partners 1 of 5 stars	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$762.00 ➝ $834.00	+19.65%
2/4/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$1,230.00 ➝ $1,030.00	+48.22%
2/4/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$950.00 ➝ $903.00	+29.95%
2/4/2025	Bernstein Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$1,070.00 ➝ $1,000.00	+44.18%
1/28/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$795.00 ➝ $750.00	+9.54%
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$1,195.00 ➝ $1,013.00	+47.20%
1/16/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1,130.00 ➝ $738.00	+4.91%
1/10/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$1,050.00 ➝ $900.00	+22.68%
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
1/8/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$1,126.00 ➝ $1,004.00	+37.48%
1/7/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,110.00 ➝ $1,070.00	+47.03%
12/17/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Newman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform	$565.00	-28.30%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,150.00	+46.96%
11/6/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,150.00 ➝ $1,000.00	+20.56%
11/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,260.00 ➝ $1,215.00	+44.97%
11/1/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,235.00 ➝ $1,184.00	+41.27%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,080.00 ➝ $1,065.00	+25.91%
10/24/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$1,250.00 ➝ $1,175.00	+24.93%
10/24/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,150.00	+22.16%
10/23/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$1,015.00 ➝ $1,015.00	+7.77%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,180.00 ➝ $1,300.00	+19.90%
6/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,170.00	+9.97%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%
3/28/2023	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$853.00 ➝ $862.00	+14.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:44 AM ET.

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, February 16, 2025. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

Regeneron Pharmaceuticals, Inc. recently reported earnings per share (EPS) of $12.07, exceeding the consensus estimate of $11.21, indicating strong financial performance and effective management.
The company achieved a revenue of $3.79 billion for the latest quarter, surpassing analyst expectations, which reflects robust demand for its products and potential for future growth.
With a current stock price of $673.60, Regeneron Pharmaceuticals, Inc. is trading significantly below its 52-week high of $1,211.20, suggesting potential for price appreciation as the market corrects.
Regeneron Pharmaceuticals, Inc. has a strong net margin of 31.07%, which indicates efficient cost management and profitability, making it an attractive option for investors seeking stable returns.
The company has a favorable average rating of "Moderate Buy" from analysts, with a consensus target price of $973.13, suggesting that many experts believe the stock is undervalued.

Regeneron Pharmaceuticals
Bear Case

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

Citigroup recently lowered its target price for Regeneron Pharmaceuticals, Inc. from $795.00 to $750.00, indicating a more cautious outlook on the stock's future performance.
The company has a relatively high price-to-earnings (P/E) ratio of 17.60, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
Despite a strong performance, one analyst has issued a sell rating on the stock, which could signal underlying concerns about the company's future prospects.
Regeneron Pharmaceuticals, Inc. has a beta of 0.08, indicating low volatility compared to the market, which may not appeal to investors looking for high-risk, high-reward opportunities.
The company has a debt-to-equity ratio of 0.09, which is low, but it may also indicate that the company is not leveraging debt to fuel growth, potentially limiting expansion opportunities.

REGN Forecast - Frequently Asked Questions

: According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $973.13, with a high forecast of $1,300.00 and a low forecast of $165.00.
: 25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 38.95% based on their 12-month stock forecasts.
: Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 upgrades and 2 downgrades by analysts.
: Regeneron Pharmaceuticals has been rated by research analysts at Bank of America, Bernstein Bank, BMO Capital Markets, Canaccord Genuity Group, Canaccord Genuity Group, Citigroup, Leerink Partners, Leerink Partnrs, Piper Sandler, Robert W. Baird, Sanford C. Bernstein, TD Cowen, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Regeneron Pharmaceuticals less than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.76 while the average consensus rating score for "medical" companies is 2.82. Learn more on how REGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:REGN) was last updated on 2/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target